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Stenting might be expected to incur a high complication rate. The stent is a foreign body producing a foreign body reaction (including giant cells) and if made of stainless steel, which carries a negative electrostatic charge, is very thrombogenic. The coronary artery might be expected to be intolerant of such a foreign body especially in the setting of potential reduced flow and following the release of prothrombogenic material (such as is present in atheroma). Initial fears appeared to have been born out when Serruys et al reported a 21% stent thrombosis rate for the wallstent in 19891 and similar results were published by Schatz for the Johnson and Johnson stent.' The obvious answer was anticoagulation, and the more the better. Thus during a second phase of coronary stenting formal anticoagulation was undertaken with warfarin, dextran, dipyridamole, aspirin, and overlapping heparin. 3 The consequence was little change in thrombosis rate4 and an excess of haemorrhagic complications, in particular femoral artery haematoma. This second period of stent anticoagulation lasted from around 1990 to 1994 during which time a number of reports appeared suggesting that stent deployment had been less than optimal5 6 most influenced the reduction in stent thrombosis from > 15% to about 2% during this third period of stenting.
The new antiplatelet regimens included ticlopidine. Ticlopidine is the only drug in current clinical practice apart from aspirin that has a true antiplatelet effect. In many ways it has potentially a more potent effect on the platelet than aspirin. Although the exact mechanism for its action is still unclear certain facts are known. First, it needs to be metabolised in the liver to a number of active metabolites for it to have any effect. There are thought to be at least four metabolites that influence platelet function. This has a number of implications. It will not be effective until an adequate plasma concentration of the metabolite(s) has been reached, which may take several days, although this has been disputed and observable antiplatelet effects have been seen within three hours of the first dose. Second, ticlopidine is not a drug that could be effective following local delivery. Because of its site of action it is likely to be more potent than aspirin not least because aspirin and ticlopidine act at different target sites in the platelet.
Aspirin inhibits the platelet through inhibition of the cyclo-oxygenase enzyme, which is an important enzyme in the metabolic pathway that converts arachidonic acid to thromboxane A2. This enzyme catalyses the production of the intermediate pathway products, the endoperoxides. The arachidonic acid pathway normally produces thromboxane A2, which stimulates other platelets and is a powerful vasoconstrictor. However, the metabolic products of the arachidonic acid pathway, inhibited by aspirin through inhibition of cyclo-oxygenase, are only one way that other platelets are stimulated (fig 1) 5-4% and for the antiplatelet agents 0-8% (relative risk, 0 14; 95% confidence interval, 0-02-0 62). Although it would appear at first glance that this study included all comers, the degree of dissection was not precisely defined between groups so the impact of a pure antiplatelet regimen in truly adverse conditions is still a little unclear. Similar results on the benefit of antiplatelet versus anticoagulant regimens are available from unpublished reports of the FANTASTIC Trial and from a number of other, some small, published trials.'3 Despite attempts to find a place for warfarin in certain circumstances, such as stenting in the setting of occlusive dissection, oral anticoagulation and the overlapping heparin are no longer used. Some still give subcutaneous heparin with antiplatelet therapy for high risk stenting as described in the earlier French trials.
Aspirin alone
Is aspirin sufficient as antiplatelet therapy or do you need the combination of aspirin and ticlopidine? There undoubtedly has been a desire to abandon ticlopidine as a treatment after stent implantation. Part of this has been the concern about complications and the initial difficulty in obtaining ticlopidine in the UK. The evidence for giving aspirin alone has been compelling. In Colombo's study with antiplatelet treatment and high pressure intravascular ultrasound, aspirin alone appeared almost as good as the combination of aspirin and ticlopidine with stent thrombosis rates of 14% and 0-8%, respectively, although the difference may have failed to achieve significance because of sample size. In a randomised trial by the same group'4 226 patients received either aspirin alone (n = 103) or a combination of short term aspirin and ticlopidine (n = 123). At one month the stent thrombosis rate was 2-9% in the aspirin group and 0-8% in the combination group, again a difference that was not significant. The authors acknowledge however that the combination of a low incidence of the end point and small numbers randomised may again have been responsible for the difference failing to achieve significance. Other randomised studies have also tended to have small numbers.
Larger trials are being done; thus we await the full publication of the MUST, STARS, and MUSIC studies. There has been preliminary presentation of results from these studies and the MUST data confirmns the low incidence of stent thrombosis with antiplatelet (aspirin and ticlopidine) therapy without the need to resort to intravascular ultrasound (IVUS) guidance but with high pressure ballooning.
STARS is a completed study using the Johnson & Johnson (Palmaz-Shatz) stent in which patients were randomised to aspirin, aspirin and warfarin, or aspirin and ticlopidine. Post-stent high pressure was used and IVUS use was optional. There was no pretreatment with ticlopidine. The trial group consisted of 55 sites in the US who have randomised 1650 patients to one of the three groups (553, 544, and 550 patients, respec-Gershlick tively). The primary end point was clinical subacute closure within 30 days (hierarchical composite of death, emergency bypass surgery, Q wave myocardial infarction, and subacute closure with repeat revascularisation within 30 days). Early data indicates that the post-stent mean deployment pressure was 16-8 atm and two thirds of patients received single stents (the mean lesion length being , and 10O3 mm in the three groups, respectively). The as yet unpublished data indicates that the end point was reached in 2-4% of the aspirin and warfarin group, but in only 0-6% of the aspirin plus ticlopidine group. However this point was reached in 3-6% of the aspirin alone group (P = 0.001). Stent thrombosis occurred in 0-6% of the aspirin and ticlopidine group but in 2-9% of the aspirin alone group, and 2-4 % of the aspirin and warfarin group (P = 0-00 1).
Early ticlopidine (0 4% transient neutropenia in STARS). Stent thrombosis is such a potential disaster (50% myocardial infarction rate) however that the use aspirin and ticlopidine in combination should be recommended. Better antiplatelet agents than ticlopidine such as clopidogrel have been developed. Future trials comparing clopidogrel and aspirin with ticlopidine and aspirin would be worth considering. Aspirin alone may be acceptable in patients in whom the stent deployment is IVUS directed or in those with large vessels or in whom low risk de novo stenting has been undertaken with heparin coated stents. '5 Whether all the studies purporting to include patients at high risk of stent thrombosis truly have included such high risk patients, and whether other groups such as those with occlusive dissection in small (< 2.8 mm) vessels will truly be protected by an oral antiplatelet combination of aspirin and ticlopidine is yet to be determined. Certainly such patients had a excess risk of thrombosis in the French registry data. A drug eluting truly antithrombotic stent is likely to be developed for these patients. Such agents will need to act, like ticlopidine, at the final glycoprotein IIb/IIIa receptor site.
